Taxifolin 7-rhamnoside Clinical Trials

Size	Price	Qty
1mg	USD 127

Clinical Trials

Several clinical trials are currently recorded in this evaluation domain, targeting diverse conditions including Chronic Obstructive Pulmonary Disease, COVID-19, Tricuspid Regurgitation, and hemoglobinopathies such as Sickle Cell Disease and Transfusion-dependent Beta-Thalassemia. Spanning Phase 4 evaluations as well as non-applicable or unassigned phase designations, these studies assess topics ranging from pulmonary treatment responses to pharmacokinetic bioequivalence in viral disease. Sponsored by a combination of academic foundations and corporate entities, these trials are currently documented as not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06334575	Not yet recruiting	Chronic Obstructive Pulmonary Disease	Maria Joyera Rodríguez\|Fundacion Clinic per a la Recerca Biomédica	2024-07	Phase 4
NCT06096571	Not yet recruiting	Viral Infection COVID-19	Valenta Pharm JSC	2024-06-15	Not Applicable
NCT06368401	Not yet recruiting	Tricuspid Regurgitation	Versa Vascular Inc	2024-06-01	Not Applicable
NCT06363760	Not yet recruiting	Sickle Cell Disease\|Transfusion-dependent Beta-Thalassemia\|Hemoglobinopathies	Editas Medicine Inc.	2024-06-04	--

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Taxifolin 7-rhamnoside product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Taxifolin 7-rhamnoside interacts with bacterial cell wall biosynthetic enzymes, inhibiting essential peptidoglycan cross-linking and disrupting membrane integrity to induce bacterial cell lysis. By attenuating pathogen viability and associated inflammatory stress, this biochemical action supports therapeutic investigation in clinical trial conditions such as Chronic Obstructive Pulmonary Disease and viral infections like COVID-19.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).